Free Trial

Intuitive Surgical (ISRG) Stock Forecast & Price Target

Intuitive Surgical logo
$545.16 +3.17 (+0.58%)
(As of 09:09 AM ET)

Intuitive Surgical - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
3
Buy
15

Based on 19 Wall Street analysts who have issued ratings for Intuitive Surgical in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 1 has given a sell rating, 3 have given a hold rating, and 15 have given a buy rating for ISRG.

Consensus Price Target

$550.28
0.94% Upside
According to the 19 analysts' twelve-month price targets for Intuitive Surgical, the average price target is $550.28. The highest price target for ISRG is $650.00, while the lowest price target for ISRG is $375.00. The average price target represents a forecasted upside of 0.94% from the current price of $545.16.
Get the Latest News and Ratings for ISRG and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Intuitive Surgical and its competitors.

Sign Up

ISRG Analyst Ratings Over Time

TypeCurrent Forecast
12/19/23 to 12/18/24
1 Month Ago
11/19/23 to 11/18/24
3 Months Ago
9/20/23 to 9/19/24
1 Year Ago
12/19/22 to 12/19/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
15 Buy rating(s)
13 Buy rating(s)
15 Buy rating(s)
17 Buy rating(s)
Hold
3 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
4 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$550.28$524.61$446.45$342.95
Forecasted Upside0.94% Upside-1.32% Downside-8.89% Downside2.15% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

ISRG Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ISRG Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Intuitive Surgical Stock vs. The Competition

TypeIntuitive SurgicalMedical CompaniesS&P 500
Consensus Rating Score
2.74
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside0.94% Upside28,497.71% Upside12.06% Upside
News Sentiment Rating
Positive News

See Recent ISRG News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/11/2024Citigroup
3 of 5 stars
 Boost TargetBuy ➝ Buy$567.00 ➝ $640.00+17.72%
12/11/2024Wells Fargo & Company
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$549.00 ➝ $630.00+15.49%
12/5/2024Stifel Nicolaus
4 of 5 stars
 Boost TargetBuy ➝ Buy$525.00 ➝ $610.00+11.22%
12/2/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$522.00 ➝ $650.00+19.93%
11/26/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$535.00 ➝ $561.00+3.85%
11/19/2024Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
Genesis leading the smart algo revolution? (Ad)

I’m revealing an exciting breakthrough that can help trade the markets unlike anything you’ve ever seen before… Because with my BRAND NEW smart algo you’ll always have a constant stream of alerts firing off in your back pocket to choose from. Here’s why: It does all the heavy lifting for you… automatically. Stock Ticker, Entry Price, Profit Target, Stop Loss, and even an Individual Chart!

You’ll want to see what I’ve put on this page right here
10/18/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Roman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$604.00+15.73%
10/18/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Perform ➝ Market Perform
10/18/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingCautious ➝ Cautious
10/18/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$495.00 ➝ $538.00+4.92%
10/18/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Shagun Singh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$525.00 ➝ $555.00+8.40%
10/17/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Anthony Petrone
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Target$440.00 ➝ $500.00+5.30%
10/17/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$489.00 ➝ $502.00+5.72%
10/17/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$503.00 ➝ $565.00+18.98%
10/14/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$500.00 ➝ $540.00+11.06%
10/14/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Richard Newitter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$520.00 ➝ $570.00+17.78%
10/11/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$495.00 ➝ $575.00+18.52%
8/2/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Ridley-Day
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$380.00 ➝ $510.00+13.10%
7/18/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$430.00 ➝ $490.00+17.49%
4/19/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$365.00 ➝ $375.00+0.64%
11/17/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$318.00+4.62%
10/19/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$385.00 ➝ $314.00+14.82%
5/31/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$350.00 ➝ $365.00+18.87%
4/19/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold$245.00 ➝ $290.00-4.27%
4/19/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$300.00 ➝ $315.00+16.98%
3/23/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Vazquez
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
12/22/2022Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$265.00 ➝ $320.00+20.23%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:46 AM ET.


Should I Buy Intuitive Surgical Stock? ISRG Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, December 12, 2024. Please send any questions or comments about these Intuitive Surgical pros and cons to contact@marketbeat.com.

Intuitive Surgical
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Intuitive Surgical, Inc.:

  • Intuitive Surgical, Inc. reported a strong quarterly earnings per share (EPS) of $1.56, exceeding the consensus estimate of $1.24 by $0.32, indicating robust financial performance.
  • The company achieved revenue of $2.04 billion for the quarter, surpassing expectations and showcasing its ability to generate significant sales.
  • With a net margin of 28.51%, Intuitive Surgical, Inc. demonstrates effective cost management and profitability, which is attractive to investors looking for financially healthy companies.
  • The stock is currently trading at $538.86, reflecting a strong market position and investor confidence, especially given its 52-week high of $556.23.
  • Analysts have a consensus rating of "Moderate Buy" for the stock, with a price target of $550.28, suggesting potential for price appreciation.

Intuitive Surgical
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Intuitive Surgical, Inc. for these reasons:

  • The stock has a high price-to-earnings (P/E) ratio of 86.63, which may indicate that it is overvalued compared to its earnings, posing a risk for potential investors.
  • Insider selling has been notable, with over 50,000 shares sold in the last three months, which could signal a lack of confidence from those within the company.
  • Despite strong performance, the company has a relatively low return on equity of 13.41%, which may suggest less efficiency in generating profits from shareholders' equity.
  • The stock's beta of 1.38 indicates higher volatility compared to the market, which could lead to greater risk for investors during market fluctuations.
  • Analysts have mixed ratings, with one sell rating and four hold ratings, indicating some uncertainty about the stock's future performance.

ISRG Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Intuitive Surgical is $550.28, with a high forecast of $650.00 and a low forecast of $375.00.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intuitive Surgical in the last year. There is currently 1 sell rating, 3 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ISRG shares.

According to analysts, Intuitive Surgical's stock has a predicted upside of 0.94% based on their 12-month stock forecasts.

Over the previous 90 days, Intuitive Surgical's stock had 2 upgrades by analysts.

Analysts like Intuitive Surgical less than other "medical" companies. The consensus rating score for Intuitive Surgical is 2.74 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ISRG compares to other companies.


This page (NASDAQ:ISRG) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners